Coulter Partners was very pleased to partner once again with innovative drug enabling nanotechnology company, Nanoform to secure the appointment of Dr David Rowe as its Head of Manufacturing. The new role will strengthen Nanoform’s manufacturing organization to efficiently deliver commercial APIs for global partners.
Locate Bio Ltd has received an additional £2.0 million of investment from Mercia Technologies PLC and its third party fund, the Midlands Engine Investment Fund to expand the application of its technologies, including its promising gene therapy technology IntraStem™, into new high value therapy areas to both broaden its in-house development pipeline and provide additional partnering opportunities.
During National Apprenticeship Week apprentices and participating employers gathered at Oxford BioMedica to discuss how the first of its kind advanced therapies apprenticeship programme is key to meeting the industry demands for advanced therapies.
Dr Ian Campbell, interim Executive Chair, Innovate UK, delivered the keynote speech and highlighted the Government’s commitment to the programme. Other highlights of the day included a Q&A session with current apprentices and the launch of three new programmes in regulatory affairs, senior management and the Scottish modern apprenticeship in life sciences.
BioDivide has developed a new stem cell technology for horses called StemPlan. The launch of StemPlan will be supported by a series of CPD events to provide veterinarians with the most up-to-date information about equine regenerative medicine.
Imperial College School of Medicine is actively seeking industry placements for students in the third year of the innovative BSc Medical Biosciences (BMB) course. During this final year, students undertake specialist modules that specifically examine health problems in the 21st century, and elect a project in either a laboratory, literature-based research project or a work placement.
Maintaining a highly skilled workforce is vital to business; I can’t imagine anyone reading this blog would dispute that. Similarly indisputable is the need for business to keep up with the latest developments in research and technology. Doctoral training partnerships can help your business to achieve both of these goals, by strengthening ties with academia, shedding light on new ways of working, and increasing recruitment of multi-skilled graduates. UKRI-BBSRC believes that partnerships with the users of research are important in shaping our doctoral training programmes through better understanding of industry’s needs, concerns and aspirations. By working with companies, UKRI-BBSRC seeks to train students capable of becoming future leaders in industry.
I attended and participated in the inaugural WuXi Healthcare Forum in Shanghai in March 2019, enabling me to gain a better insight into some of the key trends occurring in innovative life science in China today. Here are a few thoughts that I came away with.
In the last two years China has made a concerted attempt to, and has delivered, fundamental changes to key aspects of its human healthcare market as part of a broader Government push to improve healthcare for the nation and become a leader in biotechnology. They fall into four areas regulation, reimbursement, talent and capital.
I spent last week at the inaugural WuXi Healthcare Forum in Shanghai, and it proved to be a hugely insightful week, with over 2000 global leaders gathered. I spoke on a panel entitled ‘New Era, Golden Opportunities’ where leaders from China and the UK explored how key stakeholders are redefining the innovation narrative – opening up a new era of opportunities and connecting the global life sciences ecosystem. I also attended the British Consulate-General/BioIndustry Association official reception hosted by John Edwards, HM Consul General in Shanghai and Kevin Holland, Minister Counsellor of Life Sciences and Healthcare at the British Embassy in Beijing. You can read a blog on my thoughts from the forum and the other life sciences developments in China here. The UK’s China life sciences tea
Anti-microbial resistance (AMR) is undoubtedly one of mankind’s greatest healthcare challenges. This is emphasised by the fact that this crisis is a main agenda item for the United Nations, World Health Organisation, G7 and G20. Lord O’Neill, chair of the UK Review on Antimicrobial Resistance, put the future in stark contrast in his 2016 report “Tackling drug-resistant infections globally” – if significant steps are not taken to address this issue, >10 million AMR attributable deaths per annum (more than currently caused by cancer) and a total cost to the global economy of $100 trillion by 2050 is predicted.